VanEck Biotech ETF·Financial Services

IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.

Launched on December 20, 2011, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

The 2026 Brown Brothers Harriman (BBH) Global ETF Investor Survey revealed a constant data point — demand for ETFs remains robust on a global scale. However, the current market environment is shifting the tide, giving way to specific trends in an ETF marketplace that continues to evolve.

VanEck Biotech ETF (NASDAQ: BBH - Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 13th, there was short interest totaling 14,260 shares, a growth of 107.2% from the January 29th total of 6,883 shares. Based on an average trading volume of 7,038 shares,

VanEck Biotech ETF (NASDAQ: BBH - Get Free Report) and Compass Diversified (NYSE: CODI - Get Free Report) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk and profitability. Earnings and Valuation This table compares

BBH: Mature Biotech Exposure, But Limited Growth Ahead
VanEck Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.
Financial Services
Asset Management
1999-11-23
0.76
Market Peers





